Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Other Related Categories

546239, A61K 3144, C07D21134

Type

Patent

Status

active

Patent number

060280832

Description

ABSTRACT:
The present invention is directed to esters of (+)-.alpha.-(2,3 Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, pharmaceutical formulations, methods of making and methods of using these esters. These compounds antagonize the effects of serotonin at the 5HT.sub.2A receptor and are useful in treating various conditions such as, for example, psychoses such as schizophrenia.

REFERENCES:
patent: 2833775 (1958-05-01), Sperber et al.
patent: 3058979 (1962-10-01), Ullyot et al.
patent: 3194733 (1965-07-01), Yale et al.
patent: 3394131 (1968-07-01), Yale et al.
patent: 3655676 (1972-04-01), Kaiser et al.
patent: 4569941 (1986-02-01), Suh et al.
patent: 4623728 (1986-11-01), Sarges
patent: 4632929 (1986-12-01), Suh et al.
patent: 4701461 (1987-10-01), Suh et al.
patent: 4762842 (1988-08-01), Cohen et al.
patent: 4783471 (1988-11-01), Carr
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4877798 (1989-10-01), Sorensen
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 4908369 (1990-03-01), Schechter et al.
patent: 4912117 (1990-03-01), Carr
patent: 4921863 (1990-05-01), Sugimoto et al.
patent: 4950614 (1990-08-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5021428 (1991-06-01), Carr
patent: 5064838 (1991-11-01), Carr et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5100901 (1992-03-01), Sugimoto et al.
patent: 5106855 (1992-04-01), McLees et al.
patent: 5112978 (1992-05-01), Molinari
patent: 5116846 (1992-05-01), Cain et al.
patent: 5134149 (1992-07-01), Carr et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5169096 (1992-12-01), Carr et al.
patent: 5254556 (1993-10-01), Janssen et al.
patent: 5561144 (1996-10-01), Carr et al.
patent: 5618824 (1997-04-01), Schmidt et al.
patent: 5700812 (1997-12-01), Carr et al.
patent: 5700813 (1997-12-01), Carr et al.
patent: 5721247 (1998-02-01), Carr et al.
Tetrahedron: Asymmetry, vol. 4, No. 5 (pp. 943-946) (1993), King.
Tetrahedron: Asymmetry, vol. 1, No. 8 (pp. 535-536) (1990), Nieduzak.
Tetrahedron: Asymmetry, vol. 2, No. 2 (pp. 113-122) (1991), Nieduzak.
Nambu, Keiko et al., Biochemical Pharmacology, vol. 36, No. 10, pp. 1715-1722, 1987.
Dencker, Svan Jonas et al., Disease Management, CNS Drugs, 1996, Nov:6(5)367-381.
Remington's Pharmaceuticals Sciences, "Sustained-release drug delivery systems", pp. 1687-1688, 18th edition-1990.
Biopharmaceutics (1990), vol. 5, pp. 123-130, C.Hansch, et al., "Comprehensive Medicinal Chemistry." Pergamon Press, Oxford XP002105609.
Pharmazeutische Chemie (1982), pp. 14, 15 & 17, E. Schroeder et al. Georg Thieme Verlag, Stuttgart XP002105610.
Deconoate: International Clinical Psychopharmacology, No. 12 (pp. 255-261) (1997).
An electrophysiological investigation of the mechanism of action of the mechanism of action of the 5-ht2 antagonists ritanserin and mdl 28,133a on amphetamine induced slowing of a 1qO dopamine neurons, abstract of presentation at International Congress on Schizophrenic Research present in Tuscon Arizona on April 21-25, 1991, Sorensen.
Psychopharmacology (1989) 98:45-50: L. Ugedo wt al.
Drugs of the Future vol. 14, No. 5, 1989, pp. 489-490, Janssen.
Pharmacology and Toxicology Supplement 1, 1990, 5-7, E. Christensson et al.
Pharmacology and Toxicology Supplement 1, 1990, 12-17, B. Gustaffson et al.
Life Sciences, vol. 47, pp. 2401-2408, J. Frank Nash.
The Journal of Pharmacology and Experimental Therapeutics,vol. 253, No. 3, 1162-1170, Saller.
Journal of Neurochemistry, vol. 54, No. 3, 1990, 1062-1066, Nash et al.
The Journal of Pharmacology and Experimental Therapeutics, vol. 249, No. 3, 673-679, Goldstein et al.
Psychopharmacology (1989) vol. 99:S18-S27; H. Y. Meltzer.
The Journal of Pharmacology and Experimental Therapeutics, vol. 251:238-246, Meltzer et al.
4-Aroylpiperidines and Related Carbinols as Potent and Selective Inhibitors of Serotonin 5-HT2 Receptors with Antipsychotic Potential, Abstract of presentation at International Congress on Schizophrenic Research present in Tuscon Arizona on Apr. 21-25, 1991.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Esters of (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-520782

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.